LINC01977: A Long Intergenic Non-Protein-Coding RNA (G105371919)

Target Name: LINC01977

NCBI ID: G105371919

LINC01977

Other Name(s): long intergenic non-protein coding RNA 1977 | Long intergenic non-protein coding RNA 1977

LINC01977: A Long Intergenic Non-Protein-Coding RNA

Non-Protein-Coding RNAs (NP-C RNAs) have emerged as a promising source of drug targets and biomarkers due to their diverse functions in various biological processes. One of the key features of NP-C RNAs is their ability to self-regulate gene expression, which allows them to act as scaffolds for the development of complex cellular structures. In this article, we focus on LINC01977, a long intergenic non-protein-coding RNA (lncRNA), and its potential as a drug target or biomarker.

LINC01977 is a transcribed RNA molecule that contains 1,977 exons and is located between the 5' and 3' ends of chromosome 19. It is characterized by a highly conserved structure, with a predicted protein-coding domain and a non-coding region that contains multiple domains involved in various cellular processes. LINC01977 is involved in the regulation of gene expression, cell adhesion, and signaling pathways, which are critical for various biological processes, including development, growth, and reproduction.

Due to its unique structure and diverse functions, LINC01977 has been considered as a potential drug target or biomarker. One of the main reasons for this is its involvement in various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. LINC01977 has been shown to be involved in the regulation of cellular processes that are implicated in these diseases, which may provide insight into new drug targets or biomarkers.

Several studies have investigated the potential drug targets or biomarkers associated with LINC01977. One of the most promising targets is the protein p16INK4a, which is a key regulator of the T-cell receptor signaling pathway. LINC01977 has been shown to be involved in the regulation of p16INK4a expression and has been identified as a potential p16INK4a inhibitor.

Another potential drug target associated with LINC01977 is the gene PDGFRA, which is involved in the development and maintenance of tissues, including blood vessels, neural circuits, and muscles. LINC01977 has been shown to be involved in the regulation of PDGFRA expression and has been identified as a potential PDGFRA inhibitor.

In addition to its potential drug targets, LINC01977 has also been investigated as a potential biomarker for various diseases. For example, LINC01977 has been shown to be downregulated in various cancer types, including neurobladder cancer, suggesting that it may be a useful biomarker for this disease. Additionally, LINC01977 has been shown to be involved in the regulation of cellular processes that are implicated in aging, which may provide insight into new strategies for preventing age-related diseases.

In conclusion, LINC01977 is a long intergenic non-protein-coding RNA that has been shown to be involved in various cellular processes that are critical for human health and disease. Its unique structure and diverse functions make it an attractive candidate as a drug target or biomarker. Further research is needed to fully understand the role of LINC01977 in various biological processes and to develop new strategies for investigating and treating its associated diseases.

Protein Name: Long Intergenic Non-protein Coding RNA 1977

The "LINC01977 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01977 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets